Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. （開啟新視窗）

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

來源‎: Ann Intern Med 2008;148(12):939-55.

檢索‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 （開啟新視窗）

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. （開啟新視窗）

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

來源‎: Am J Hematol 2000;64(1):26-31.

檢索‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 （開啟新視窗）

Hydroxyurea for the treatment of sickle cell anemia. （開啟新視窗）

Platt OS.

來源‎: N Engl J Med 2008;358(13):1362-9.

檢索‎: PubMed 18367739

DOI碼‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 （開啟新視窗）

Clinical effectiveness of decitabine in severe sickle cell disease. （開啟新視窗）

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

來源‎: Br J Haematol 2008;141(1):126-9.

檢索‎: PubMed 18324975

DOI碼‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 （開啟新視窗）

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). （開啟新視窗）

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

來源‎: Blood 2010;115(12):2354-63.

檢索‎: PubMed 19903897

DOI碼‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 （開啟新視窗）

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. （開啟新視窗）

Hirst C, Owusu-Ofori S.

來源‎: Cochrane Database Syst Rev 2012;(9):CD003427.

檢索‎: PubMed 22972063

DOI碼‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 （開啟新視窗）

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. （開啟新視窗）

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

來源‎: Lancet Haematol 2021;8(5):e323-33.

檢索‎: PubMed 33838113

DOI碼‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 （開啟新視窗）

Sickle cell disease. （開啟新視窗）

Meremikwu MM, Okomo U.

來源‎: BMJ Clin Evid 2011;02:2402.

檢索‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 （開啟新視窗）

A phase 3 trial of l-glutamine in sickle cell disease. （開啟新視窗）

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

來源‎: N Engl J Med 2018;379(3):226-35.

檢索‎: PubMed 30021096

DOI碼‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 （開啟新視窗）

Malaria chemoprophylaxis in sickle cell disease. （開啟新視窗）

Oniyangi O, Omari AA.

來源‎: Cochrane Database Syst Rev 2006;(4):CD003489.

檢索‎: PubMed 17054173

DOI碼‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 （開啟新視窗）